Roger S. Newton, Director at Esperion Therapeutics, Inc. (ESPR), sold 25,000 shares at $73.26 ($1.8M) on 2018-03-29, disclosed to the SEC on 2018-03-29.
Open-market sale of $1.8M ESPR by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $70.71 | 200 | $14K | 0.8% |
| 2 | $71.36 | 7,100 | $507K | 28.0% |
| 3 | $72.31 | 8,656 | $626K | 34.6% |
| 4 | $73.26 | 9,044 | $663K | 36.6% |
| Total | $72.37 avg | 25,000 | $1.8M | 100% |
| Filing → |
| ESPR | SELL | 2018-10-18 | $1.7M | — | Filing → |
| ESPR | SELL | 2018-08-29 | $904K | — | Filing → |
| ESPR | SELL | 2018-08-22 | $365K | — | Filing → |